Literature DB >> 20051860

Why do patients with schizophrenia smoke?

Georg Winterer1.   

Abstract

PURPOSE OF REVIEW: Among the mentally ill, smoking prevalence is highest in patients with schizophrenia ( approximately 70-80%). This can impose a significant financial burden on patients, not to speak of increased smoking-related morbidity and mortality. Therefore, it is critical for clinicians to understand why patients with schizophrenia smoke in order to adapt treatment schemes. Understanding the reasons may also help to develop new drugs that target the nicotinic system in the brain as well as smoking cessation programs that are specifically designed for this particular patient population. RECENT
FINDINGS: So far, several reasons have been identified which are believed to explain tobacco consumption in patients with schizophrenia. Originally, it was widely believed that patients with schizophrenia smoke to increase hepatic clearance and to restore the dopamine blockade of certain antipsychotic drugs to diminish their side effects. However, more recently it became obvious that cigarette smoking may also be reinforcing for patients because it improves psychiatric symptoms, most notably negative and cognitive symptoms. The underlying molecular mechanisms of these nicotine effects are currently under intensive investigation.
SUMMARY: Heavy smoking in schizophrenia cannot simply be viewed as a 'bad habit'. Rather, self-medication of clinical symptoms and side effects of antipsychotic drugs appear to play a major role.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051860     DOI: 10.1097/YCO.0b013e3283366643

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  69 in total

1.  Tobacco craving in smokers with and without schizophrenia.

Authors:  Suzanne Lo; Stephen J Heishman; Heather Raley; Katherine Wright; Heidi J Wehring; Eric T Moolchan; Stephanie Feldman; Fang Liu; Robert P McMahon; Charles M Richardson; Deanna L Kelly
Journal:  Schizophr Res       Date:  2010-07-15       Impact factor: 4.939

Review 2.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

3.  The role of nicotinic acetylcholine receptors in the medial prefrontal cortex and hippocampus in trace fear conditioning.

Authors:  J D Raybuck; T J Gould
Journal:  Neurobiol Learn Mem       Date:  2010-08-19       Impact factor: 2.877

4.  The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?

Authors:  C Quisenaerts; M Morrens; W Hulstijn; E de Bruijn; M Timmers; J Streffer; J De la Asuncion; G Dumont; B Sabbe
Journal:  Psychopharmacology (Berl)       Date:  2014-02       Impact factor: 4.530

5.  Nicotinic modulation of salience network connectivity and centrality in schizophrenia.

Authors:  Jason Smucny; Korey P Wylie; Eugene Kronberg; Kristina T Legget; Jason R Tregellas
Journal:  J Psychiatr Res       Date:  2017-02-03       Impact factor: 4.791

6.  Higher psychological distress is associated with unintentional injuries in US adults.

Authors:  Jana McAninch; Christina Greene; John D Sorkin; Marie-Claude Lavoie; Gordon S Smith
Journal:  Inj Prev       Date:  2013-10-30       Impact factor: 2.399

7.  Preservation Effect: Cigarette Smoking Acts on the Dynamic of Influences Among Unifying Neuropsychiatric Triple Networks in Schizophrenia.

Authors:  Wei Liao; Yun-Shuang Fan; Siqi Yang; Jiao Li; Xujun Duan; Qian Cui; Huafu Chen
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

8.  Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Authors:  Anne Schmechtig; Jane Lees; Lois Grayson; Kevin J Craig; Rukiya Dadhiwala; Gerard R Dawson; J F William Deakin; Colin T Dourish; Ivan Koychev; Katrina McMullen; Ellen M Migo; Charlotte Perry; Lawrence Wilkinson; Robin Morris; Steve C R Williams; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2013-02-22       Impact factor: 4.530

Review 9.  Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.

Authors:  Jason Smucny; Jason R Tregellas
Journal:  J Psychopharmacol       Date:  2017-04-26       Impact factor: 4.153

10.  Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.

Authors:  S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott
Journal:  Neuroscience       Date:  2013-03-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.